What factors drove the changes in Scholar Rock Holding's revenue and profit?

What were the key takeaways from Scholar Rock Holding’s earnings call?

What were the key takeaways from Scholar Rock Holding's earnings call?

What does Scholar Rock Holding do and what are its main business segments?

Did Scholar Rock Holding beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for Scholar Rock Holding year over year?

What is the market's earnings forecast for Scholar Rock Holding next quarter?

What is Scholar Rock Holding's latest dividend and current dividend yield?

- **2026 Regulatory Milestone**: BLA resubmission and U.S. launch on track, contingent on successful FDA reinspection of the Catalent facility.
- **Pipeline Expansion**: SRK-439 Phase I enrollment complete; subcu apitegromab Phase I data supports PK comparability to IV.
- **Financial Strength**: $368M cash on hand + $550M debt facility provide >$900M liquidity post-approval.
- **Commercial Readiness**: U.S. launch infrastructure built with 140 SMA centers and 10,000+ home infusion nurses.
- **European Expansion**: EMA decision expected mid-2026, with Germany as the first European launch market.

**【CEO Summary Section】**
- Scholar Rock reaffirms 2026 guidance for BLA resubmission and U.S. launch of apitegromab, with FDA reinspection of the Catalent Indiana facility as the key gating factor.
- Progress with a second fill/finish facility is advancing, with engineering runs underway and plans to submit a supplemental BLA later this year.
- European MAA review continues, with an EMA decision expected mid-2026.
- Commercial launch preparations in the U.S. and Europe are progressing, including disease education programs and specialty pharmacy partnerships.
- The anti-myostatin pipeline is expanding with SRK-439 Phase I enrollment and expected top-line data in H2 2026.

**【CFO Financial Commentary】**
- Ended 2025 with $368 million in cash, including $60.4 million from warrant exercises.
- Secured a new $550 million debt facility to support commercial launch and R&D, with $100 million drawn immediately and additional $100 million available by Q2.
- Monetization of a priority review voucher post-approval will further strengthen the balance sheet.
- Operating expenses for 2025 were $384.6 million, excluding stock-based compensation.

**【Q&A Key Highlights】**
- **Regulatory Progress**: FDA engagement remains high, with no new requests for Novo's remediation plan. A successful reinspection would trigger BLA resubmission.
- **Supply Chain**: Second fill/finish facility is on track for supplemental BLA submission in 2026, providing redundancy.
- **Commercial Strategy**: U.S. launch expected in H2 2026, with Germany as the first European market. Patient access programs and specialty pharmacy networks are operational.
- **Pipeline Updates**: Subcu apitegromab Phase I data shows comparable PK to IV; Phase II FSHD study to begin this year with 60 patients.
- **Financial Flexibility**: Debt facility and voucher monetization provide $650 million+ in liquidity post-approval.

Scholar Rock Holding Corporation(SRRK)-20260303-2025 Q4 Earnings call transcript

- **Revenue Growth & Market Recovery**: 15% YoY revenue increase driven by SMA treatment demand in North America.
- **Apitegromab Regulatory Progress**: FDA Type A meeting highlights shared urgency for approval, with reinspection of Bloomington facility expected by year-end. Second fill/finish facility secured for 2026 launch.
- **Financial Strength**: $420M GAAP net income, Non-GAAP EPS of $1.12, and $369.6M cash runway into 2027. Debt prioritized to minimize dilution.
- **Pipeline Expansion**: Phase II OPAL study initiated for apitegromab in infants, and SRK-439 IND cleared for Phase I in 2026.
- **Operational Redundancy**: Second fill/finish facility ensures supply chain resilience, with tech transfer commencing Q1 2026.


**【CEO Summary Section】**
- Scholar Rock reported third-quarter revenue growth driven by a 15% year-over-year increase in the North American market, attributed to the recovery in SMA (spinal muscular atrophy) treatment demand.
- CEO David Hallal emphasized the company's strategic focus on advancing apitegromab, the first muscle-targeted therapy for SMA, with regulatory submissions expected in 2026 following FDA reinspection of the Bloomington facility.
- The company secured a second fill/finish facility for apitegromab, with tech transfer commencing in Q1 2026, ensuring redundancy in supply chain to mitigate risks from the Bloomington facility's compliance status.
- Gross margin improvement is expected in the second half of 2026, supported by cost control measures and disciplined capital allocation.

**【CFO Financial Commentary】**
- Third-quarter GAAP net income was $420 million, with Non-GAAP EPS exceeding expectations at $1.12, reflecting strong operational efficiency.
- Operating expenses were $103 million, including $18.3 million in stock-based compensation, with a focus on R&D and commercial readiness for apitegromab.
- The company strengthened its balance sheet with $91.7 million from an ATM and $50 million debt draw, providing a cash runway into 2027.
- Vikas Sinha highlighted the prioritization of investments in apitegromab's second fill/finish facility, SMA commercial launch, and Phase II OPAL study, ensuring alignment with strategic goals.

**【Q&A Key Highlights】**
- **Regulatory & Supply Chain**: The FDA's Type A meeting confirmed shared urgency for apitegromab's approval, with Novo Nordisk's Bloomington facility expected to be reinspection-ready by year-end. The company secured a second fill/finish facility to ensure seamless commercial launch, with tech transfer underway.
- **Financial Strategy**: CFO Vikas Sinha emphasized debt as the preferred financing option to minimize dilution, with ATM usage as a supplementary tool. The company aims to expand its credit facility while preserving non-dilutive financing options.
- **Market Access & Launch Readiness**: Keith Woods highlighted pre-commercial engagement with 140 SMA treatment centers and over 2,600 prescribing physicians, focusing on muscle-targeted therapy education and access expansion.
- **Pipeline Progress**: Akshay Vaishnaw announced the initiation of the Phase II OPAL study for apitegromab in infants and toddlers, and the IND clearance for SRK-439, a subcutaneously administered myostatin inhibitor, with Phase I studies expected to begin in 2026.

**【Risk & Contingency】**
- If the Bloomington facility's reinspection fails to resolve compliance issues, the company plans to pivot to the second fill/finish facility, with potential sBLA filing to maintain the 2026 launch timeline. This contingency underscores the company's operational flexibility and commitment to patient access.


Scholar Rock Holding Corporation (SRRK) Q3 2025 Earnings Call Transcript

- **FDA Approval Imminent**: BLA under priority review with September 22 PDUFA date; late cycle meeting reaffirms timeline. 
- **SAPPHIRE Success**: Apitegromab delivers 3x higher motor function gain vs. placebo in SMA patients on SMN therapies. 
- **Commercial Readiness**: U.S. launch team fully deployed; 600+ patient years of supply ready. 
- **Financial Strength**: $295M cash, $50M debt facility available; runway extends into 2027. 
- **Pipeline Expansion**: Phase II OPAL trial for infants <2 years; SRK-439 IND filing late 2025.

**【Management Opening Remarks】**
- **Regulatory Milestones**: BLA for apitegromab under priority review with PDUFA date of September 22, 2025. MAA filed in EU, targeting mid-2026 approval. 
- **CDMO Inspections**: Observations noted at two CDMOs, responses submitted; FDA late cycle meeting reaffirmed commitment to PDUFA timeline. 
- **Commercial Ambition**: U.S. launch pending approval, followed by Europe (Germany first), Asia Pacific, and Latin America. 
- **Pipeline Expansion**: Planning additional neuromuscular indications for apitegromab; IND for SRK-439 expected late 2025.

**【R&D Update】**
- **SAPPHIRE Trial**: Apitegromab demonstrated statistically significant motor function improvement (3x higher Hammersmith gain vs. placebo) in SMA patients on SMN-targeted therapies. 
- **EMBRAZE Study**: Apitegromab + tirzepatide increased lean mass preservation by 54% (p=0.001) in obesity, supporting anti-myostatin platform. 
- **New Indications**: Phase II OPAL trial for infants <2 years launching Q3; DMD and FSHD preclinical models show promise. 
- **Pipeline**: SRK-439 IND filing planned for late 2025 as next anti-myostatin candidate.

**【Commercial Readiness】**
- **U.S. Launch Prep**: Field team fully deployed, engaging SMA centers and payers. 600+ patient years of clinical supply ready for launch. 
- **Payer Dynamics**: 20%+ SMA patients already on dual therapies; apitegromab's durability and unmet need for muscle preservation driving positive discussions. 
- **Global Strategy**: EU launch in 2026, with Germany first; targeting 35,000 global SMA patients on SMN therapies.

**【Financial Commentary】**
- **Cash Position**: $295M as of Q2, with $50M debt facility available post-approval. Anticipated $16M from warrant exercises by year-end. 
- **Runway**: Financial planning extends into 2027; $50M debt facility available for launch support. 
- **PRB Utilization**: Priority review voucher expected to generate meaningful value post-approval.

**【Q&A Highlights】**
- **Regulatory Confidence**: FDA late cycle meeting constructive; no reinspection required, PDUFA date maintained. 
- **Label Expectations**: Broad label for 2+ years old SMA patients; adult data consistency supports expanded use. 
- **Pricing Strategy**: SMA rarity, severity, and apitegromab's unique mechanism justify premium pricing. 
- **Pipeline Expansion**: Multiple anti-myostatin assets in pipeline; SRK-439 IND filing on track for late 2025.

Scholar Rock Holding (SRRK)-6 Aug 25-2025 Q2 Earnings call transcript

- **FDA Priority Review**: Apitegromab granted priority review with Sept 22, 2025 PDUFA date, reflecting SMA's unmet need.
- **SAPPHIRE Success**: Trial showed 3x higher likelihood of 3+ Hammersmith points gain vs. placebo, with strong safety profile.
- **Global Launch Readiness**: $364.4M cash, $100M debt facility, and 50-person commercial team in place for Q3 2025 US launch.
- **EMBRAZE Milestone**: Phase 2 obesity trial results expected June 2025 to assess muscle preservation potential.

**【CEO Opening Remarks】**
- Q1 2025 marked significant progress toward launching apitegromab for SMA, with FDA granting priority review (PDUFA date: Sept 22, 2025) and positive Phase 3 SAPPHIRE trial results showing motor function improvement vs. placebo.
- Global commercial readiness underway, targeting US launch in Q3 2025, followed by Europe, APAC, and Latin America. Nearly 35,000 SMA patients globally have received SMN-targeted therapies.
- Exploring apitegromab in additional neuromuscular indications (e.g., DMD, FSHD) and cardiometabolic obesity via EMBRAZE Phase 2 trial (results expected June 2025).

**【CFO Financial Update】**
- Q1 2025 cash balance: $364.4M; $100M debt facility available to support launch, extending runway to 2027.
- Investments focused on commercial readiness (e.g., 50-person sales/reimbursement team), inventory build, and pipeline advancement (e.g., SRK-439 IND filing in Q3 2025).
- Disciplined capital allocation strategy to balance near-term launch and long-term pipeline growth.

**【Q&A Key Themes】**
- **Pricing & Access**: US payers receptive to combination therapy; global launches sequenced to start in US (Sept 2025), followed by Germany (2026). No adcom requested by FDA.
- **Regulatory Update**: FDA interactions constructive; priority review reflects unmet need in SMA.
- **Obesity Trial (EMBRAZE)**: 24-week data to assess lean mass preservation vs. tirzepatide; 8-week follow-up to monitor weight regain trajectory.
- **Pipeline Expansion**: Preclinical data support apitegromab in DMD/FSHD; SRK-439 IND filing on track for Q3 2025, with optionality in neuromuscular and cardiometabolic spaces.

Scholar Rock Holding Corporation (SRRK) Q1 2025 Earnings Call Transcript

- **SMA Regulatory Milestone**: BLA submitted in U.S., MAA in EU by March 2025; 30% of SMA patients achieved ≥3-point Hammersmith improvement.
- **Muscle Preservation Breakthrough**: EMBRAZE study shows 20-40% reduction in lean mass loss with apitegromab + tirzepatide, comparable weight loss to tirzepatide alone.
- **Cardiometabolic Pipeline**: SRK-439 IND filing in Q3 2025; preclinical data shows 4x potency vs. anti-ACTRII antibodies.
- **Commercial Readiness**: 50-person commercial team onboarded; home infusion services planned for U.S. launch Q4 2025.
- **FDA Engagement**: Company navigating obesity trial guidance by incorporating lean mass loss metrics, while advocating for functional endpoints.


**【CEO Opening Remarks】**
- Submitted BLA for apitegromab in the U.S. in January 2025, with MAA submission in the EU planned for March 2025.
- Presented positive SAPPHIRE data showing 1.8-point improvement in Hammersmith Functional Motor Scale (p < 0.001) vs. placebo, with 30% of patients achieving ≥3-point improvement.
- Highlighted potential for apitegromab to become the first approved muscle-targeted therapy for SMA, with a U.S. launch expected in Q4 2025.
- Announced IND filing for SRK-439 (anti-myostatin) in Q3 2025, targeting cardiometabolic indications.

**【Tracey Sacco - Commercial Update】**
- Launched 'Life Takes Muscle' campaign to educate on progressive muscle weakness in SMA.
- Expanded commercial team to ~50 employees, including sales, reimbursement, and patient support.
- Initiated payer outreach in Q1 2025, with focus on demonstrating value of apitegromab as a combination therapy.
- Planning home infusion services at launch to support patient access.

**【Jay Backstrom - Cardiometabolic Programs】**
- EMBRAZE study (Phase 2b) with apitegromab + tirzepatide showed 20-40% reduction in lean mass loss vs. tirzepatide alone, with comparable weight loss at Week 24.
- SRK-439 demonstrated superior myostatin inhibition in preclinical models, with potential for subcutaneous dosing.
- Filed IND for SRK-439 in Q3 2025, targeting 52-week study to assess fat regain mitigation.

**【Q&A Highlights】**
- **FDA Guidance on Obesity Trials**: Company expects to meet FDA requirements by including lean mass loss assessment in trials, while advocating for functional endpoints like grip strength.
- **Neuromuscular Expansion**: Exploring DMD, FSHD, and ALS indications, with nonclinical data showing apitegromab efficacy in DMD models.
- **Pricing Strategy**: Payers have expressed openness to combination therapy coverage; pricing will align with SMA market norms.
- **SRK-439 Differentiation**: Preclinical data shows 4x greater potency than anti-ACTRII antibodies, with potential for lower doses.


Actual							-0.58	-0.65	-0.79	-0.79	-0.76	-0.84	-1.02	-0.97	-0.21	-1.06	-0.55	-0.44	-0.49	-0.47	-0.53	-0.4978	-0.59	-0.6	-0.66	-0.62	-0.67	-0.98	-0.9	-0.88
Forecast							0.012	-0.522	-0.5275	-0.61	-0.678	-0.7499	-0.816	-0.9885	-0.57	-0.9598	-0.64	-0.5288	-0.5225	-0.5325	-0.4958	-0.4664	-0.4832	-0.5904	-0.5801	-0.6012	-0.6807	-0.6648	-0.8423	-0.9018
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-4933.33%	-24.52%	-49.76%	-29.51%	-12.09%	-12.01%	-25.00%	+1.87%	+63.16%	-10.44%	+14.06%	+16.79%	+6.22%	+11.74%	-6.90%	-6.73%	-22.10%	-1.63%	-13.77%	-3.13%	+1.57%	-47.41%	-6.85%	+2.42%

Actual	--	--	--	--	--	--	5.03M	3.90M	3.04M	3.43M	4.71M	4.59M	5.46M	4.05M	33.19M	0	0	3.00K	0	0	0	0	0	0	0	0	0	0	0	0
Forecast	--	--	--	--	--	--	24.81M	6.85M	7.63M	6.51M	6.00M	5.20M	4.64M	4.40M	22.13M	0	0	0	0	0	0	0	0	0	0	0	0	0	55.56K	0
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-79.72%	-43.06%	-60.21%	-47.30%	-21.54%	-11.63%	+17.78%	-8.07%	+49.98%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-100.00%	0.00%

SRRK

SRRK fundamentals

SRRK Q4 2025 Earnings

Earnings Call

You can ask Aime

SRRK

SRRK fundamentals

SRRK Q4 2025 Earnings

Earnings Call

SRRK Earnings Call Summary for Q4/20258:00 AM on Mar 3, 2026

SRRK Earnings Call Summary for Q3/20258:00 AM on Nov 14, 2025

SRRK Earnings Call Summary for Q2/20258:00 AM on Aug 6, 2025

SRRK Earnings Call Summary for Q1/20258:15 AM on May 14, 2025

SRRK Earnings Call Summary for Q4/20248:15 AM on Feb 27, 2025

You can ask Aime